I missed the beginning of the call as well. It's archived now, however, so..... at your leisure.
In the release, they said 250K patients in U.S. for PA.
Nuvance..... not particularly of interest to me at this cap. I realize that it's of interest to older shareholders, but..... until after hours today, I have never owned it. Or, I owned it years ago and have forgotten. I'm interested in (1) ENBREL for psoriasis (not just psoriatic arthritis), (2) CD40L, and (3) TRAIL/Apo2 ligand.
They seemed sincere in still having an interest in the steroid-dependent population. Point made in a couple of different ways, that IL-4 may be of significantly greater interest in those receiving steroids.
"The committee's recommendation was from lack of efficacy." That is great information at this market cap..... no downside (apparent) for the existing business, for a product that is pointing at the huge psoriasis market and for which there is apparently qualifying data for psoriatic arthritis.
Last quarter annualized at $1 billion. $1.6B in cash, market cap of $5.4B at 17:00 EST. Down from 52 week high of $70/share. Positive news today for PA indication. This after hours reaction is, IMO, hilarious.
Details given re. Rhode Island facility schedule. Guidance continues to be $750M for ENBREL this year. They're trying to squeeze more product out of current providers.
Initial capacity at RI facility will be about $1 billion of product/year. There will be additional capacity at RI later, and AHP is considering options in Ireland.
DO NOT MISS THE ARCHIVED CALL!
Good luck, all! |
